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Fierce competition to gain market share is revolutionizing the cannabis industry and, as 
companies invest significant monetary resources to remain competitive in an evolving sector, a 
new era in cannabis production emerges. 
This report aims to explore the potential of cannabis biosynthesis and how it is reshaping 
traditional production, beginning with a brief description of what this new concept entails and 
the advantages it has. It also provides an analysis over the implications and opportunities that 
can be created, with an outlook of the investments and partnerships already made, ultimately 
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Cannabis Biosynthesis is the newly promising technology that holds the prospect to be 
remarkably disruptive to the cannabis industry. So far, Canopy Growth and its peers have been 
investing in expansion strategies, either organically or through acquisitions, increasing their 
cultivation capacity in Canada and Internationally. Accordingly, during the first year of 
legalization, total active cultivation area grew to 19 million square feet, representing an annual 
growth rate around 400%1. However, if cannabis biosynthesis proves to be a feasible reality, 
one can wonder what impact that might have on cannabis companies and how it will reshape 
the actual production process.  
Biosynthesis Definition & Advantages Over Traditional Cannabinoids Extraction  
Cannabis Biosynthesis is a natural, alternative method of producing cannabinoids (i.e. 
marijuana’s active components), through a process that genetically modifies an organism to 
produce a pharmaceutically bioactive compound, from simple substance by living organisms 
such as bacteria, yeast or algae2. Hence, the more than 100 cannabinoids like CBD or THC, 
identified in cannabis plants, can potentially be produced without having to grow the pot plant.  
Although this method is estimated to only become a commercial reality within 18 to 24 months 
3from now, it can be especially important for generating cannabinoids other than THC and 
CBD, as these minor cannabinoids,  are much more difficult to produce from plants, but 
potentially have unique applications4.  
According to Rahul Sarugaser of Paradigm Capital, replacing in-the-filed crop cultivation by 
biosynthesis production has several advantages and is the future of cannabis:  
“The cannabis plant is a relatively inefficient biological factory. 95 per cent of its volume tends 
 
1 Cannabis Benchmarks. 2019. “Canada cannabis spot index”. Accessed December 2019. https://reports.cannabisbenchmarks.com/canada/ 
2 Alen Brochstein. 2019. “How biosynthesis of cannabinoids couldimpact the cannabis industry. Accessed 2019. https://renewbiopharma.com/how-biosynthesis-
of-cannabinoids-could-impact-the-cannabis-industry/ 
3 Nick Waddel. 2019. “Biosynthesis is the future of cannabis, not plant cultivation, Paradigm Capital says”. Accessed December 2019. 
https://www.cantechletter.com/2019/01/biosynthesis-is-the-future-of-cannabis-not-plant-cultivation-paradigm-capital-says/ 




to end up as biomass waste. By volume, the principal cannabinoids, THC and CBD, make up 
just approximately two to five per cent of the plant, while minor cannabinoids and terpenes —
hundreds of them— comprise less than 0.1 per cent.” 5 
Hence, the edge Biosynthesis has over traditional extraction methods relies on the creation of 
cannabinoids with higher purity, higher quality control and decreased costs, with a much 
smaller carbon footprint. 
Contrarily to synthetic production, which only produces molecules similar to naturally 
occurring cannabinoids6, it is foreseen that biosynthesis will generate cannabinoids that 
conceive the exact same compounds that would be produced from traditional cannabis 
extraction, and that are not significantly observed in the cannabis plant itself, offering a level 
of consistency that is not possible to replicate in crops, which are subjected to climate 
conditions, plagues and other environmental ambiguities.  
Biosynthesis is also more environmentally friendly since less energy is required to run a 
bioreactor than to power the grow lights and ventilation fans of an indoor cannabis-growing 
operation. Furthermore, less water is needed, and land devastation related to outdoor cannabis 
cultivation can also be reduced, by eliminating the use of fertilizers and pesticides, also saving 
money on those resources. Moreover, biosynthesis preserves from the difficult, expensive and 
time-consuming challenges of planting, growing and harvesting cannabis, for then laboriously 




5 Rahul Sarugaser. 2018. “Cannabinoid Biosynthesis: Engineering the Most Disruptive Technology in the Cannabis Industry”.  
6 Hugo Gray. 2019. “Weed Science – How Biosynthesis will Upend the Cannabis Industry”. Accessed December 2019. https://thegreenfund.com/weed-science-
how-biosynthesis-will-upend-the-cannabis-industry 




Implications & Opportunities for the Cannabis Industry 
The main allure of biosynthesis technology really relates to the opportunity to reduce costs, 
mitigating the current tendency of decreasing margins that cannabis companies are dealing 
with. Is estimated that with biosynthesis production, the expenses related with land, equipment 
and energy will decrease, allowing to recreate cannabinoids in high quantitates, at less than 
US$1 per gram8.  
Accordingly, there are considerable discrepancies between the production levels that traditional 
plantations can attain and what is possible to produce in laboratories: while in one year of 
traditional cannabis cultivation might provide 4 to 6 harvests, a single bioreactor can surpass 
23 harvests and create nearly 1,000 metric tons of cannabinoids annually in a 1 million square-
foot facility designated for biosynthesis production. Whereas if the same 1 million square-foot 
was intended for a greenhouse, it would yield around 16 metric tons per year9. 
Biosynthesis can also generate impact on already established segments of the industry. The new 
cannabis production method can, not only unveil new pharmaceutical opportunities that might 
further enhance the medical cannabis market, currently estimated to reach US$57 billion by 
202510, but also impact the derivatives market, estimated to be C$2.7 billion annually11. Hence, 
shall this technology prove to be feasible, and these segments might incorporate biosynthesis 
cannabinoids instead of the ones originally extracted from the plant, diminishing part of the 
demand for dried flower products. 
Nonetheless, there will always be market for plant-derived pot products, in part due to customer 
requirements for “naturally sourced” cannabis products, and the relatively low capital 
investment needed in traditional extraction operations. 
 
8 Greg Miller. 2019. “Biosynthesis finds its way into these leading cannabis stocks”. Accessed December 2019. 
https://nicinvestors.com/2019/07/05/biosynthesis-finds-its-way-into-these-leading-cannabis-stocks/ 
9 Maxx Chatsko. 2019. “Will Cannabis Producers Ditch Greenhouses for Bioreactors?”. Accessed December 
2019.https://www.fool.com/investing/2019/03/01/will-cannabis-producers-ditch-greenhouses-for-bior.aspx 
10 IMARC Group. 2019. “Medical Cannabis Market”. Accessed December 2019. https://www.imarcgroup.com/medical-cannabis-market 




Outlook of Investments and Partnerships with Biopharma and Biotechnology Companies 
Aware of cannabis biosynthesis disruptive power, and concerned with increasing market 
saturation and compressed margins, some major Canadian Licensed Producers (Canopy’s 
competitors), are positioning themselves to capitalize on the shift, by partnering with 
Biopharma and Biotechnology companies that are working on refining the process. 
Hence, in September 2018, the Boston-based Ginkgo Bioworks, landed a deal worth 
approximately US$122 million with Cronos Group, to produce cannabinoids via biosynthesis.  
Then, in May 2019, Canadian LP Organigram Holdings invested C$10 million in Montreal-
based Hyasynth Biological, to purchase cannabinoids produced by Hyasynth.  
Canopy Growth also expresses accordance with the idea that investments made in biosynthesis 
can turn to be huge differentiators for investors looking for a cannabis player with an edge.  
In an interview in October 2019, Narbe Alexandrian, the chief executive of the venture capital 
arm of Canopy Growth Corporation, Canopy Rivers, said that he anticipates “the real disruptors 
will be companies that are focusing on generating cannabinoids other than THC and CBD” 12. 
Alexandrian anticipates making an investment in the biosynthesis space within the next year 
and said that the company has spoken with more than 50 companies across the globe, adding it 
is “just a matter of executing”. Nonetheless, during 2019 Canopy continued to invest in 
production capacity expansion, falling behind its peers that started making investments in 









Future Prospects for the Cannabis Market 
It will take time for the promise of lab-grown cannabinoids to deliver, but while biosynthesis 
still has not demonstrated itself as an expandable production method, it can potentially 
revolutionize the way cannabinoids are produced in the near future, and organizations that 
competent to succeed in integrate biosynthesis, will likely benefit from a key advantage over 
their competitors. 
Nonetheless, if this new method proves successful, several cannabis production companies, 
Canopy Growth included, could be left with needless assets, namely the considerable active 
cultivation area. Although the dried flower will continue to have market, part of the 4.8 million 
square feet of indoor and greenhouse production capacity that allowed Canopy to harvest 
46,927 kilograms of cannabis in 2019, might become unnecessary.  
Besides all the advantages presented, companies that are investing in biosynthesis can further 
leverage their edge in what relates to legalization, since cannabinoid compounds produced 
through the new method might be more likely to be exempt from the regulatory hurdles 
governing the cannabis cultivation sector, as they did not originate in the plant itself13. 
 
 
13 Hugo Gray. 2019. “Weed Science – How Biosynthesis will Upend the Cannabis Industry”. Accessed January 2019. https://thegreenfund.com/weed-science-
how-biosynthesis-will-upend-the-cannabis-industry 
